Jeito Capital Raises Record $1.2 Billion for Jeito II Fund, Largest Ever for Independent European Biopharma Fund

on

Jeito Capital closed its second fund, Jeito II, at over €1 billion ($1.2 billion), exceeding its target and claimed as the largest raise ever for a fully independent European biopharma-focused fund.123

The fund will invest in 15-20 clinical-stage biopharma companies, primarily in Europe, with up to €150 million per company, focusing on breakthrough therapies for severe diseases.123

Jeito's first fund closed at €534 million ($630 million) in 2021; the new fund triples assets under management to €1.6 billion.135

Portfolio successes include acquisitions of Neogene by AstraZeneca ($200M, 2022), EyeBio by Merck ($1.3B upfront, 2024), and Hi-Bio by Biogen ($1.15B upfront, 2024).13

Recent investment:
participated in $197M Series A for Alveus Therapeutics in February.1

Rafaèle Tordjman, founder, called it a strong signal for the European biopharma ecosystem.12

Sources:

1. https://www.biopharmadive.com/news/jeito-capital-biopharma-venture-fund-billion/816946/

2. https://www.fiercebiotech.com/biotech/jeito-hails-12b-largest-raise-ever-independent-biopharma-focused-european-fund

3. https://www.cityam.com/jeito-capital-hits-record-1-2-billion-e1-billion1-close-for-jeito-ii-fund-to-drive-breakthrough-therapeutic-innovation-for-patients/

5. https://techfundingnews.com/jeito-capital-1b-biopharma-fund-europe/